40098-44-0

Usage

InChI:InChI=1/C14H22O3/c1-2-17-14(16)11-6-4-3-5-8-12-9-7-10-13(12)15/h9H,2-8,10-11H2,1H3

Upstream product

• 64-17-5 ethanol 
• 5239-43-0 7-(5-oxo-1-cyclopenten-1-yl)heptanoic acid 
• 74845-23-1 ethyl 2-(6-carbethoyxhexyl)cyclopentanone-5-glyoxalate 
• 52477-94-8 2-(6,6-dicarbethoxyhexyl)-1-methoximino-2-cyclopentene 
• 5239-91-8 2-(6-carbethoxyhexyl)-2-carbethoxycyclopentanone 
• 7732-18-5 water 
• 52477-95-9 1-methoximino-2-(6,6-dicarboxyhexyl)-2-cyclopentene 
• 52477-96-0 1-methoximino-2-(6-carboxyhexyl)-2-cyclopentene 
• 41301-67-1 1-acetoxy-2-(6-carbethoxyhexyl)-1-cyclopentene 
• 10472-24-9 methyl 2-oxocyclopentane-1-carboxylate 
• 52477-90-4 1-acetoxy-2-(5-acetoxypentyl)-1-cyclopentene 
• 40098-46-2 2-(4-carbethoxybutyl)cyclopent-2-en-1-one 
• 41301-58-0 2-(6-carbethoxyhexyl)-2-carbomethoxycyclopentanone 
• 35074-08-9 2-(4-carboxybutyl)cyclopentan-1-one 

Downstream Products

• 5239-43-0 7-(5-oxo-1-cyclopenten-1-yl)heptanoic acid 
• 34546-57-1 2-(6-methoxycarbonylhexyl)cyclopent-2-en-1-one 
• 24341-38-6 11-Deoxy-13-dihydroprostaglandin E(1) 
• 41301-75-1 1-methoximino-2-(7-p-toluenesulfonyloxyheptyl)-2-cyclopentene 
• 40098-40-6 (+/-)-11,15-Didesoxyprostaglandin E⁽¹⁾ 
• 109707-48-4 11,15-Didesoxy-13-cis-14-phenyl-16,17-didehydro-18,19,20-trinorprostaglandin E₁ 
• 109707-48-4 7-[(1S,5S)-2-Oxo-5-((E)-2-phenyl-penta-1,4-dienyl)-cyclopentyl]-heptanoic acid 
• 84284-14-0 2-(2-carboxyethyl)-2-cyclopenten-1-one 
• 84310-14-5 2-(4-carboxybutyl)-2-cyclopenten-1-one 
• 95733-58-7 S(-)-2-(4-carboxy-3-hydroxybutyl)-2-cyclopenten-1-one 

Relevant academic research and scientific papers

TOTAL SYNTHESIS OF PROSTAGLANDINS. IV*. SYNTHESIS OF 2-(6-ALKOXYCARBONYLHEXYL)CYCLOPENT-2-EN-1-ONES

A preparative method was developed for the synthesis of 2-(6-alkoxycarbonylhexyl)cyclopent-2-en-1-ones by the bromination of the respective 2-(6-alkoxycarbonylhexyl)cyclopentan-1-ones with N-bromosuccinimide, followed by dehydrobromination of the bromine-substituted compounds and isomerization of the 2-(6-alkoxycarbonylhexylidene)cyclopentan-1-ones formed as side products.

Novel 2-substituted-3,4-epoxycyclopentan-1-ones, 2-substituted-3,4-epoxycyclopentan-1-ols, and various 2-substituted-cyclopentenones

This disclosure describes novel 4-oxy-2-substituted-cyclopent-2-en-1-ones useful as intermediates for the preparation of homo and nor prostaglandins of the E2, E3 and F series.

Novel 11-hydroxy-9-keto-5,6-cis-13,14-cis-prostadienoic acid derivatives

This disclosure describes certain 11-hydroxy and 11-deoxy-9-keto(or hydroxy)-prostanoic acid derivatives useful as bronchodilators, hypotensive agents, anti-ulcer agents, or as intermediates.

Hydro substituted prostanoic acids and esters

This disclosure describes certain 11-hydroxy and 11-deoxy-9-keto (or hydroxy)prostanoic acid derivatives useful as bronchodilators, anti-ulcer agents, or as intermediates.

1-Alkoximino-2-(ω-substituted alkyl)-2-cyclopentenes

This disclosure describes certain 1-alkoximino-2-(ω-substituted-alkyl)-2-cyclopentenes useful as intermediates for the preparation of homologues, analogues, congeners, and derivatives of 9-oxo-13-trans-prostenoic acid and of 9-hydroxy-13-trans-prostenoic acid which have antimicrobial activity and prostaglandin-like hypotensive activity.

Derivatives of 9-hydroxy-13-trans-prostenoic acid

This disclosure describes certain 15-deoxy prostanoic acid derivatives having a hydroxy group further along in the beta-chain, useful as bronchodilators, hypotensive agents, anti-ulcer agents, or as intermediates.

3-Alkyl-2-(6-carboxyhexyl)cyclopentanones and esters and salts thereof

This disclosure describes compounds of the class of substituted 9-oxoprostanoic acids and the esters and cationic salts thereof, useful as antimicrobial agents, hypotensive agents, anti-ulcer agents, or as intermediates, and novel processes for preparing the same.

Derivatives of 9-oxo-13-trans-prostenoic acid esters

This disclosure describes homologues, analogues, congeners, and derivatives of 9-oxo-13-trans-prostenoic acid and of 9-hydroxy-13-trans-prostenoic acid, having antimicrobial activity and prostaglandin-like hypotensive activity.

13-Sulfa-prostaglandins

Sulfides of the general formula SPC1 Wherein R1 is H or alkyl, R2 is =O, (H,OH), or (H,lower-acyloxy), R3 is H, OH or lower-acyloxy, R4 is alkyl or alkyl substituted by F, OH, lower-acyloxy, phenyl or p-tolyl, and A is alkylene which can be mono- or polysubstituted by F, and the physiologically acceptable salts thereof, possess, in addition to a blood-pressure-lowering activity, prostaglandin-type and antiprostaglandin-type effects.